The benefit of a vaccine that is effective, far outweighs the risk, and especially in hard-to-reach vulnerable populations. — C.D.C. Panel
The benefit of a vaccine that is effective, far outweighs the risk, and especially in hard-to-reach vulnerable populations. — C.D.C. Panel
C.D.C. Panel Recommends Lifting J.&J. Vaccine Pause



A panel of advisers to the Centers for Disease Control and Prevention on Friday recommended restarting Johnson & Johnson Covid-19 vaccinations, saying that the benefits outweighed the minuscule risk of blood clotting.

So the vote is 10 in favor, four opposed, and one abstention. The motion carries. The Janssen Covid vaccine is recommended for persons 18 years of age and older in the U.S. population under the F.D.A.’s emergency use authorization. Thank you all very much. Our preliminary considerations would be supportive of reaffirming the recommendation for use of this vaccine. It’s well recognized that persons in the Black and brown community have been disproportionately affected by this pandemic. So the benefit of a vaccine that is effective, far outweighs the risk, and especially in hard-to-reach vulnerable populations.
Read the full article: https://www.nytimes.com/video/us/100000007727891/johnson-vaccine-restart-approved.html